Jordi brings more than 27 years of experience across medical devices, health tech, and venture, with leadership roles spanning Boston Scientific, Verily, and a portfolio of neurotech companies including Cala Health, INSIGHTEC, Rune Labs, Lotus Neuro, and Galvani.

This is a practical conversation about what neurotech needs next, from patient access and indication expansion to reimbursement, market access, consumer devices, and smarter investment thinking.

We also explore Jordi’s perspective on the future of neuromodulation, brain data, wearable technologies, BCI, focused ultrasound, and why the next phase of the industry will depend on connecting innovation across the full patient journey.

Key takeaways:

🔹 Why neurotech still needs to solve its patient access and penetration problem

🔹 How consumer and regulated devices could work together across the healthcare journey

🔹 What early-stage neurotech investors look for beyond financial modelling

🔹 Why reimbursement and market access are becoming central to funding and M&A

🔹 Where Jordi sees the next major opportunities in neuromodulation and neuropsychiatric care

Host:

Chay Carter

Founder, Carter Sciences

Co-Founder, Reccy Neuro

LinkedIn: https://www.linkedin.com/in/chay-carter/

Guest:

Jordi Parramon

Neurotechnology investor, operator, and founder of Nexus NeuroTech Ventures
LinkedIn: https://www.linkedin.com/in/jordi-parramon-50b2158/

Key Chapters:

00:00 Introduction to Jordi Parramon
01:16 From Implantable Devices to Neurotech Investment
04:28 M&A, Platforms, and Early Neuromodulation Innovation
08:57 Patient Access and Indication Diversification
11:19 Wearables, Consumer Devices, and Neurohealth
16:43 EEG, Brain Data, and the Future of Digital Health
18:05 What Investors Look for in Neurotech
28:22 Emerging Opportunities and the Future of Neuromodulation

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

🔔 Subscribe for weekly conversations with the founders, researchers, and operators building what comes next in brain health, medicine, and technology.

Jennifer shares the story behind Tivic’s journey, from consumer bioelectronics and non-invasive stimulation to FDA clearance, retail launch, IPO, supply chain disruption, and a major pivot into biopharma.

This is a practical conversation about the rollercoaster journey of building regulated consumer neurotechnology, bringing a new category to market, and navigating the strategic decisions founders face when timing, capital, and market conditions change. 

We also look ahead to the future of bioelectronic medicine, including peripheral nerve stimulation, AI-native company building, and how electrical and pharmaceutical approaches could eventually work together.

Key takeaways:

🔹 Why “going consumer” is not always the easier route for neurotech companies

🔹 What founders need to understand about category creation, claims, and customer acquisition

🔹 How Tivic navigated FDA clearance, retail launch, IPO, and supply chain disruption

🔹 Why remote monitoring, reimbursement, and physician incentives matter for device adoption

🔹 How AI, peripheral nerve stimulation, and bioelectronic medicine could shape the next phase of neurotech

Host:

Chay Carter

Founder, Carter Sciences

Co-Founder, Reccy Neuro

LinkedIn: https://www.linkedin.com/in/chay-carter/

Guest:

Jennifer Ernst

Founder and former CEO of Tivic Health (now Valion Bio)

LinkedIn: https://www.linkedin.com/in/jenniferernst/

Key Chapters:

00:00 Introduction to Jennifer Ernst and Tivik Health
03:28 The Journey into Bioelectronics and Neurotechnology
07:01 Consumer Market Challenges in Neurotechnology
10:02 Navigating the IPO Process and Supply Chain Issues
14:01 Lessons Learned from the Tivik Experience
17:39 The Future of Neurotechnology and AI Integration
23:09 Vagus Nerve Stimulation and Its Potential
28:51 Transitioning to Biopharmaceuticals and Future Directions

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

George shares how Brainomix is building clinical AI software to support treatment decisions in stroke and fibrosing lung disease, helping clinicians extract meaningful information from medical scans and use it in time-critical patient pathways.

This is a practical conversation about what it takes to move healthcare AI from algorithm performance into real clinical adoption. We explore why AI is only valuable when it integrates into workflows, supports clinician decision-making, and improves patient outcomes.

We also discuss Brainomix’s journey from Oxford spinout to NHS adoption, Series C growth, and US expansion, as well as the company’s work with hospitals, pharma partners, and clinical trials.

Key takeaways:

🔹 Why stroke care depends on faster identification and treatment decisions

🔹 Why clinical AI needs workflow integration, not just strong algorithms

🔹 How Brainomix is applying imaging AI across stroke and fibrosing lung disease

🔹 What it takes to drive adoption across hospitals, healthcare systems, and the US market

🔹 Why the future of healthcare AI will depend on evidence, implementation, and patient impact

Host:

Chay Carter

Founder, Carter Sciences

Co-Founder, Reccy Neuro

LinkedIn: https://www.linkedin.com/in/chay-carter/

Guest:

Dr. George Harston

Chief Medical and Innovation Officer at Brainomix

LinkedIn: https://www.linkedin.com/in/george-harston-3b9496b1/

Key Chapters:

00:00 Introduction to Brainomix and Dr George Harston
04:01 From Stroke Medicine to Clinical AI
06:54 Why AI Needs to Fit the Clinical Workflow
12:30 How Imaging AI Can Improve Patient Outcomes
18:25 Expanding AI Support into Fibrosing Lung Disease
24:19 Navigating US Healthcare, Reimbursement, and Adoption
30:09 The Future of Stroke Treatment and Clinical AI
36:23 Brain Data, Personalised Medicine, and What Comes Next

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

Dan shares how Nia is developing a closed-loop neurostimulation system designed to help patients with memory loss, combining implantable sensing, machine learning, wearable components, and personalised stimulation.

This is a practical conversation about the future of cognitive BCIs, what it takes to move neurotechnology from academic research into clinical development, and why memory restoration could become one of the most important frontiers in the field.

We also explore Nia’s FDA Breakthrough Device Designation for TBI-related memory loss, the evolution of BCI over the last 20 years, the reality behind cognitive enhancement hype, and why efficacy matters more than form factor when building neurotechnology for patients.

Key takeaways:

🔹 How Nia Therapeutics is developing closed-loop neurostimulation for memory loss

🔹 Why cognitive BCIs could become a major new category in neurotechnology

🔹 What FDA Breakthrough Device Designation means for clinical development

🔹 Why direct-to-consumer cognitive enhancement still needs stronger evidence

🔹 How the neurotech field is evolving from research breakthroughs to real patient impact

Host:
Chay Carter
Founder, Carter Sciences
Co-Founder, Reccy Neuro
LinkedIn: https://www.linkedin.com/in/chay-carter/

Guest:
Dr. Dan Rizzuto
President and Chief Technology Officer at Nia Therapeutics
LinkedIn: https://www.linkedin.com/in/rizzuto/

Key Chapters:
00:00 Introduction to Dan Rizzuto and Nia Therapeutics
02:23 Closed-Loop Neurostimulation for Memory Loss
05:09 From Motor BCIs to Cognitive Applications
09:40 How Nia’s Implantable and Wearable System Works
12:00 Cognitive Enhancement, Ethics, and Future Possibilities
14:09 FDA Breakthrough Device Designation and Regulatory Pathways
16:18 Fundraising, Clinical Trials, and What Comes Next
21:22 Emerging Modalities, Brain Data, and the Future of Neurotech

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

Owen shares his personal journey through bipolar disorder, his experience as a clinical trial participant, and how those experiences shaped his mission to build the future of “brain medicine”.

This is a wide-ranging conversation on transcranial magnetic stimulation (TMS), neurotechnology, AI biomarkers, precision psychiatry, and what it really takes to scale brain-based treatments in the real world.

We also explore the future of neuromodulation, patient-centred care, and why Owen believes psychiatry is evolving into a much broader field of brain medicine.

Key takeaways:

🔸 How Owen’s personal experience with bipolar disorder led him into neurotechnology
🔸 Why TMS changed his view of mental health treatment
🔸 How AI biomarkers could help predict which treatments work for patients
🔸 Why Owen believes “mental health” should be reframed as “brain medicine”
🔸 What it takes to scale patient-centred neurotechnology in the real world

Host:

Chay Carter

Founder, Carter Sciences

Co-Founder, Reccy Neuro

LinkedIn: https://www.linkedin.com/in/chay-carter/

Guest:

Dr. Owen Scott Muir MD, DFAACAP

Interventional Psychiatrist
Co-founder & Chief Medical Officer

LinkedIn: https://www.linkedin.com/in/owen-muir-md-dfaacap-fctmss-53345b7/

Key Chapters:

00:00 Introduction to Dr. Owen Scott Muir

02:21 Personal Journey and Mental Health Experiences

05:57 Clinical Trials and the Future of Mental Health Treatment

09:49 Understanding Transcranial Magnetic Stimulation (TMS)

13:06 The Evolution of TMS Treatments

26:57 AI Biomarkers and Precision Psychiatry

35:58 Building a Patient-Centric Brain Medicine Company

46:22 The Future of Neurotechnology and Brain Medicine

The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.

🔔 Subscribe for more conversations with the founders, researchers, and operators building the future of brain medicine.

#Neurotechnology #Neurotech #BrainMedicine #TMS #Neuromodulation #MentalHealth #PrecisionPsychiatry #AIHealthcare #BrainComputerInterface #Neuroscience #HealthcareInnovation #ClinicalResearch #DigitalHealth #TheOpenLoop #LifeScience #Podcast